22:00 , Jul 3, 2019 |  BC Extra  |  Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
17:38 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA...
02:35 , Feb 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bladder cancer; breast cancer; colorectal cancer; melanoma; sarcoma Mouse studies suggest inhibiting DDR2 could enhance the efficacy of anti-PD-1 therapies for bladder, breast and colorectal cancers, melanoma and sarcoma. In mouse models of bladder...
16:59 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

FDA clears Bio-Rad's PCR system as first digital PCR products

Bio-Rad Laboratories Inc. (NYSE:BIO) said its digital PCR system is the first to receive FDA clearance. FDA cleared the QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS...
19:43 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

EC approves BMS's Sprycel for pediatric ALL

The European Commission approved Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with chemotherapy to treat pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval covers both tablet and...
20:40 , Jan 18, 2019 |  BC Week In Review  |  Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Anxiety Mouse studies suggest depleting senescent cells could help treat obesity-induced anxiety. In a transgenic mouse model of obesity expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased anxiety-like...
01:46 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

FDA approves BMS's Sprycel for pediatric ALL

FDA approved an sNDA from Bristol-Myers Squibb Co. (NYSE:BMY) to expand the label of Sprycel dasatinib to include treatment of pediatric patients ages one and older with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....